A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1263-1271

  Jiang, Guan ^a   Jiang, Ai Jun ^a   Cheng, Qian ^a   Tian, Hui ^a   Li, Lian Tao ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Interleukin 24; Melanoma; Oncolytic adenoviruses; Temozolomide

Indexed keywords

E1A PROTEIN; HEXON PROTEIN; INTERLEUKIN 24; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOLYTIC ADENOVIRUS; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOWN REGULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MELANOMA CELL; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOVIRUS; CELL CYCLE; CELL PROLIFERATION; ENZYME IMMUNOASSAY; GENE THERAPY; GENE VECTOR; GENETICS; MELANOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL CULTURE; VIROLOGY; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKINS; KI-67 ANTIGEN; MELANOMA; ONCOLYTIC VIROTHERAPY; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84877115802     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0701-7     Document Type: Article

References (26)

1. La Porta CA. Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets. 2009;9:391-7.
2. Shah GD, Socci ND, Gold JS, Wolchok JD, Carvajal RD, Panageas KS, et al. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol. 2010;21:1718-22.
3. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, et al. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther. 2003;304:661-8.
4. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res. 2005;11:3402-9.
5. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2001;7:781-7.
6. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther. 2009;16:473-88.
7. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res. 2006;16:740.
8. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-6.
9. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6:1134-9.
10. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-63.
11. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517-25.
12. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50.
13. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174-83.
14. Wang MJ, Pei DS, Qian GW, Yin XX, Cheng Q, Li LT, et al. p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells. Tumour Biol. 2011;32:905-12.
15. Pei DS, Qian GW, Tian H, Mou J, Li W, Zheng JN. Analysis of human Ki-67 gene promoter and identification of the Sp1 binding sites for Ki-67 transcription. Tumour Biol. 2012;33:257-66.
16. Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, et al. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther. 2010;128:375-84.
17. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther. 2009;8:391-400.
18. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood). 2008;233:21-31.
19. Oida Y, Gopalan B, Miyahara R, Branch CD, Chiao P, Chada S, et al. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation. Mol Cancer Ther. 2007;6:1440-9.
20. Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, et al. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008;7:3842-51.
21. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 2006;16:879-86.
22. Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ, Zheng JN. Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis. Cancer Lett. 2010;28(294):220-8.
23. Jiang G, Zhang K, Jiang AJ, Xu D, Xin Y, Wei ZP, et al. A conditionally replicating adenovirus carrying interleukin-24 sensitizes melanoma cells to radiotherapy via apoptosis. Mol Oncol. 2012;6:383-91.
24. Eberle J, Fecker LF, Hossini AM, Kurbanov BM, Fechner H. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol. 2008;17:1-11.
25. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 2002;62:6089-98.
26. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther. 2009;8:980-7.